First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study
Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5630-5641
DOI: 10.1021/acs.molpharmaceut.6c00763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 25.09.2026. Verfasst von Yi Tian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang110001, Liaoning, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Peptides, Cyclic, Radiopharmaceuticals, Gelatinases. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Liaoning Provincial Science and Technology Program Joint Plan Project, Liaoning Revitalization Talents Program, National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Sufficient tumor uptake and retention, and high tumor-to-kidney ratio are highly relevant for fibroblast activation protein (FAP)-targeted tracers as imaging companions for theranostic development. Although FAP-2286 improves tumor retention versus early-generation FAPI tracers, its extended renal residence limits its application as a radiopharmaceutical therapy. We benchmarked FXX489, a next-generation cyclic peptide FAP ligand, against FAP-2286 preclinically and evaluated first-in-human [68Ga]Ga-FXX489 PET/CT to support its translational development for FAP-directed theranostics. [68Ga]Ga-FXX489 showed stronger FAP affinity than [68Ga]Ga-FAP-2286, including higher cellular uptake, lower efflux, and lower IC50. In HT-1080-hFAP xenografts, [68Ga]Ga-FXX489 achieved higher tumor uptake and retention on micro-PET and ex vivo biodistribution, and a higher tumor-to-kidney ratio. In patients (n = 10), [68Ga]Ga-FXX489 was well tolerated, and detected all 12 primary lesions (mean SUVmax, 11.20 ± 3.24) and all 42 metastatic lymph nodes (100% [42/42] vs 74% [31/42] for [18F]FDG, P < 0.001), while visualizing gastric cancer lesions with higher uptake than [18F]FDG in a paired comparison. [68Ga]Ga-FXX489 improves tumor retention and tumor-to-kidney ratio compared to [68Ga]Ga-FAP-2286 while maintaining specific FAP targeting. First-in-human [68Ga]Ga-FXX489 PET/CT shows promising detection of primary and metastatic lesions, supporting further clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang110001, Liaoning, China.
ORCID-Profile: Xuena Li
Förderung
- Liaoning Provincial Science and Technology Program Joint Plan Project
- Liaoning Revitalization Talents Program
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Tian, Y., Ying, L., Wang, Y., Wang, S., Li, X., Li, Y., & Li, X. (2026). First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study. Molecular Pharmaceutics, 23(11), 5630-5641. https://doi.org/10.1021/acs.molpharmaceut.6c00763
Vancouver
Tian Y, Ying L, Wang Y, Wang S, Li X, Li Y, et al. First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study. Molecular Pharmaceutics. 2026;23(11):5630-5641. doi:10.1021/acs.molpharmaceut.6c00763
BibTeX
@article{Tian2026,
author = {Tian, Yi and Ying, Leyi and Wang, Yuxiang and Wang, Shu and Li, Xuefei and Li, Yaming and Li, Xuena},
title = {First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {11},
pages = {5630--5641},
doi = {10.1021/acs.molpharmaceut.6c00763}
}
EUVIMED